I. COMMENCED TRADING IN MARCH

Company (Symbol)

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

INITIAL OFFERINGS

Andromed Inc. (MSE:AD; subsidiary of Theratechnologies Inc.; Canada)1

3/14

3/26

2.56U

C$2.25 (US$1.43)

N/A

National Bank Financial Inc. Desjardins Securities Inc. Hampton Securities Inc.

C$5.75 (US$3.65)

N/A

Seattle Genetics Inc. (SGEN)2

11/20

3/7

7S

$7

29.19

J.P. Morgan Securities Inc. CIBC World Markets Corp. Bank of America Securities LLC

$49

$44.4

Total: $52.65M

Number of IPOs in March: 2

Average value of March IPOs: $26.33M

Number of IPOs for 2001: 7

Total raised in IPOs in 2001: $265.75M

Average value of IPOs in 2001: $37.96M

Notes:

Unless otherwise indicated, shares are traded on the Nasdaq exchange. MSE = Montreal Stock Exchange

1 Andromed's public offering was conducted on the Montreal Stock Exchange. Each unit is comprised of one share and half a warrant.

2 Seattle Genetics' underwriters have an overallotment option for 1M shares.

FOLLOW-ON OFFERINGS

Charles River Laboratories Inc. (NYSE:CRL)3

2/15

3/16

3.5S

$19

39.4

Credit Suisse First Boston Lehman Brothers Inc. (joint leads)

$66.5

$62.5

Hemosol Inc. (Canada; TSE:HML)4

1/18

3/1

8.05S

US$8.78

N/A

UBS Warburg LLC Dain Rauscher Wessels

US$70.7

US$65

Regeneron Pharmaceuticals Inc. (REGN)5

1/25

3/20

6.5S

$25

40.8

Merrill Lynch & Co. J.P. Morgan Chase & Co. Robertson Stephens Inc.

$162.5

$153.6

Total: $299.7

Number of follow-on offerings in March: 3

Average value of March follow-ons: $99.9M

Number of follow-on offerings in 2001: 10

Total raised in follow-ons in 2001: $986.97M

Average value of follow-ons in 2001: $98.7M

Notes:

Unless otherwise indicated, shares are traded on the Nasdaq exchange. NYSE = New York Stock Exchange; TSE = Toronto Stock Exchange

3 Charles River's public offering was for 7M shares, 3.5M sold by the company and another 3.5M sold by selling stockholders. The underwriters exercised their overallotment option for 1.05M shares, sold by stockholders.

4 Hemosol's underwriters exercised in full their overallotment option for 1.05M shares, which is included in the figures.

5 Regeneron's offering was for 7M shares, 500,000 of which were offered by a shareholder. The underwriters have an overallotment option to purchase an additional 1.05M shares.

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

Acadia Pharmaceuticals Inc. (ACAD)1

12/21

5S

$13-15

15.8

Robertson Stephens Inc. (co-lead) U.S. Bancorp Piper Jaffray (co-lead)

$75

APBiotech (APBI; unit of Nycomed Amersham plc)2

10/3

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead) Goldman, Sachs & Co. (co-lead) Chase H&Q Salomon Smith Barney

$291.2

Athersys Inc. (ATHX)3

10/12

N/A

N/A

N/A

Credit Suisse First Boston Dain Rauscher Wessels ING Barings LLC

$115

BioMedicines Inc. (BIOS)4

11/3

N/A

N/A

15

UBS Warburg LLC U.S. Bancorp Piper Jaffray Pacific Growth Equities

$57.5

BioNumerik (BNPI)5

3/5

N/A

N/A

N/A

Morgan Stanley Dean Witter UBS Warburg LLC SG Cowen Securities Corp.

$50

BioTissue Technologies AG (Germany)6

11/29**

1S

EUR27-34

N/A

Landesbank Baden-Wuerttemberg Equinet Securities AG Direkt Anlage Bank AG

EUR27 (US$23)

CombiMatrix Corp. (CLMX)7

11/22

N/A

N/A

N/A

Salomon Smith Barney (co-lead) J.P. Morgan & Co. (co-lead)

$100

diaDexus Inc. (DDXS)8

11/20

7S

$12-14

31.1

Lehman Brothers Inc. CIBC World Markets Corp. Fidelity Capital Markets

$91

DNA Sciences Inc. (DNAS)9

1/8

N/A

N/A

N/A

Lehman Brothers Inc. CIBC World Markets Corp. Dain Rauscher Wessels Inc.

$125

Dynavax Technologies Corp. (DVAX)10

12/5

N/A

N/A

N/A

Bank of America Securities LLC UBS Warburg (joint leads)

$75

Kinetek Pharmaceuticals Inc. (Canada)11

10/20

N/A

N/A

N/A

N/A

N/A

NetGenics Inc. (NTGC)12

3/13/00

5.5S

$11-13

23.5

Chase H&Q UBS Warburg LLC

$66

Senomyx Inc. (SNMX)13

2/21

N/A

N/A

17.4

Deutsche Banc Alex. Brown Bear, Stearns & Co. Inc. CIBC World Markets Corp.

$80

Xcyte Therapies Inc. (XCYT)14

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead) U.S. Bancorp Piper Jaffray (co-lead) Dain Rauscher Inc. First Security Van Kasper Inc.

$86.2

FOLLOW-ON OFFERINGS

Aastrom Biosciences Inc. (ASTM)15

12/7

6.35S

$1.27

33.84

N/A

$8.1

Alexion Pharmaceuticals Inc. (ALXN)16

10/6

N/A

N/A

N/A

N/A

$300

Alteon Inc. (AMEX:ALT)17

3/5

N/A

N/A

N/A

N/A

$50

Atrix Laboratories Inc. (ATRX)18

2/15

4S

$25

13.64

N/A

$100

Cell Pathways Inc. (CLPA)19

2/8

N/A

N/A

N/A

N/A

$25

CV Therapeutics Inc. (CVTX)20

1/4

N/A

N/A

N/A

N/A

$400

InSite Vision Inc. (AMEX:ISV)21

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co. (placement agent)

$40

Medarex Inc. (MEDX)22

12/22

N/A

N/A

N/A

N/A

$500

Microcide Pharmaceuticals Inc. (MCDE)23

2/12

N/A

N/A

N/A

N/A

$35

NeoTherapeutics Inc. (NEOT)24

1/3

N/A

N/A

N/A

N/A

$50

Oxford BioMedica plc (UK; LSE:OXB)25

3/12

73.7

US$0.19

N/A

Self-managed

#10 (US$14.64)

PPL Therapeutics plc (Scotland; LSE:PTH)26

3/16

N/A

N/A

N/A

Deutsche Bank AG

#45 (US$64.2)

Scios Inc. (SCIO)27

1/19

6.4S

$18.625

38.5

N/A

$120

Transkaryotic Therapies Inc. (TKTX)28

12/13

N/A

N/A

N/A

N/A

$500

Xoma Ltd. (XOMA)29

11/17

10S

$11.25

N/A

N/A

$112.5

III. WITHDRAWN OR POSTPONED

INITIAL OFFERINGS

Company (Symbol/Proposed Symbol)*

Date Filed/Date Pulled

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value

DoubleTwist Inc. (DBLT)30

9/1 3/9

5S

$13-15

24.2

Lehman Brothers Inc. Dain Rauscher Wessels Thomas Weisel Partners LLC Fidelity Capital Markets

$70

FOLLOW-ON OFFERINGS

Digene Corp. (DIGE)31

2/7 3/19

2.125S

$36.45

18.8

Goldman, Sachs & Co. S.G. Cowen Securities Corp. ABN AMRO Rothschild LLC

$77.5

Medicure Inc. (Canada; CDNX:MPH)32

2/28 3/13

12.5U

C$1.60 (US$1.03)

21

GroomeCapital.com Inc. Wellington West Capital Inc. (placement agents)

C$20 (US$12.9)

Packard BioScience Co. (PBSC)33

2/9 3/30

3S

$15

70.7

Merrill Lynch, Pierce, Fenner & Smith Credit Suisse First Boston J.P. Morgan Securities Inc. Bank of America Securities LLC Robert W. Baird & Co.

$45

The Medicines Co. (MDCO)34

1/8 3/19

4S

$16.953

29.3

J.P. Morgan & Co. (co-lead) Robertson Stephens Inc. (co-lead) CIBC World Markets Corp. U.S. Bancorp Piper Jaffray

$67.812

Notes:

* Stock symbols for companies seeking to complete IPOs are proposed. **Denotes the date the item ran in BioWorld International.

Unless otherwise indicated, shares are traded on the Nasdaq exchange. AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange

1 Acadia's underwriters have an overallotment option for 750,000 shares.

2 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

3 Athersys did not disclose any further details.

4 BioMedicines did not disclose any further details.

5 BioNumerik filed for a $50M IPO. The number of shares to be offered, the price range, and the number of shares outstanding were not disclosed.

6 BioTissue's IPO filing is for Frankfurt's Neuer Markt. There is a greenshoe of 117,000 shares available to the underwriters.

7 CombiMatrix did not disclose any further details.

8 diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

9 DNA Sciences did not disclose any further details.

10 Dynavax did not disclose any further details.

11 Kinetek's proposed IPO was filed in Canada. No further details were disclosed.

12 NetGenics' IPO's value, $66M, is based on the sale of 5.5M shares at $12 each, the midpoint of the expected price range. The underwriters have an overallotment option for 825,000 shares.

13 Senomyx did not disclose any further details.

14 Xcyte did not disclose any further details.

15 Aastrom's offering value, $8.1M, is based on the proposed maximum aggregate price of $1.27 per share for 6.35M shares.

16 Alexion filed a shelf registration to offer common stock, debt or warrants, up to a value of $300M.

17 Alteon filed a shelf registration statement to sell $50M in shares.

18 Atrix filed to put 4M shares on the shelf. The value of the proposed offering, $100M, is based on the Feb. 15 closing stock price of $25.

19 Cell Pathways filed a shelf registration for the sale of $25M in common stock.

20 CV filed a shelf registration to sell up to $400M in debt securities, preferred and common stock and warrants

21 InSite filed a shelf registration to sell $40M in stock

22 Medarex filed a shelf registration statement to offer up to $500M of common stock, preferred stock, warrants and debt securities.

23 Microcide filed a shelf registration for the sale of up to $35M in securities.

24 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M.

25 Oxford's offering is for 73.7M shares and is being done concurrently with a private placement of 172.3M shares.

26 PPL's underwriter has an option for an additional 2.7M shares to cover overallotments. No further details were disclosed.

27 Scios filed to sell 6.4M shares under a shelf registration. The value of the offering, $120M, is based on the Jan. 17 closing stock price of $18.625.

28 Trankaryotic Therapies filed a shelf registration statement for the sale of up to $500M in securities.

29 Xoma filed a shelf registration statement for the sale of up to 10M shares. The value, $112.5M, is based on the Nov. 16 closing price.

30 DoubleTwist withdrew its bid for an IPO.

31 Digene withdrew its proposed public offering, citing unfavorable market conditions.

32 Medicure terminated its proposed financing under its prospectus filed 2/28.

33 Packard BioScience postponed the offering for 10M shares, 3M to be offered by the company and 7M to be offered by selling stockholders, due to market conditions.

34 The Medicines Co. withdrew its proposed public offering, citing unfavorable market conditions.

No Comments